Arcutis appoints Latha Vairavan as CFO; David Topper to retire effective May 15, 2025

Arcutis Biotherapeutics, Inc.

Latha Vairavan appointed SVP and CFO effective prior to Q1 10-Q filing; David Topper to retire with transition support through May 15, 2025.
Vairavan's base salary increased to $450,000, target annual bonus 45% of salary (max 67.5%), pro-rated for 2025.
Vairavan granted option to purchase 60,000 shares and 20,000 restricted stock units with standard vesting.
Topper's retirement not due to any dispute; he will receive severance benefits per existing agreement subject to release.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Topper

Chief Financial Officer

ARQT · Arcutis Biotherapeutics, Inc.

Effective: 2025-05-15
Successor: Latha Vairavan
Filed: April 10, 2025, 7:59 PM ET

Mr. Topper will continue to serve as the Company’s Chief Financial Officer until the effective date of Ms. Vairavan’s appointment and will provide transition support through his departure on May 15, 2025.

Appointed

Latha Vairavan

Senior Vice President and Chief Financial Officer

ARQT · Arcutis Biotherapeutics, Inc.

Filed: April 10, 2025, 7:59 PM ET

On April 10, 2025, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of Latha Vairavan, the Company’s current Vice President, Finance and Corporate Controller, as the Company’s Senior Vice President and Chief Financial Officer, effective immediately prior to the filing of the Company’s Quarterly Report on Form 10-Q for the three months ending March 31, 2025 with the Securities and Exchange Commission.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Topper departed as Chief Financial Officer at Arcutis Biotherapeutics, Inc..

Action: retire
Role: Chief Financial Officer

Exact text from the filing

Mr. Topper will continue to serve as the Company’s Chief Financial Officer until the effective date of Ms. Vairavan’s appointment and will provide transition support through his departure on May 15, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Latha Vairavan was appointed as Senior Vice President and Chief Financial Officer at Arcutis Biotherapeutics, Inc..

Action: appointed
Role: Senior Vice President and Chief Financial Officer

Exact text from the filing

On April 10, 2025, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of Latha Vairavan, the Company’s current Vice President, Finance and Corporate Controller, as the Company’s Senior Vice President and Chief Financial Officer, effective immediately prior to the filing of the Company’s Quarterly Report on Form 10-Q for the three months ending March 31, 2025 with the Securities and Exchange Commission.

View on SEC.gov

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-25-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.